Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
Patients
HCPs
Worldwide
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts & Japan offices
History
Worldwide Offices
Executive Leadership
Positions
Takeda Global Headquarters
Life at Takeda
Design Concept
Where we work
Corporate Philosophy
Our People
Values and Corporate Governance
Corporate Governance
Risk & Crisis Management
Global Ethics & Compliance / Global Code of Conduct
Transparency Disclosures
From the CEO
Contact Us
Celebrating the grand opening of Takeda Global Headquarters
LEARN MORE
What We Do
Our Business
We will become a global, values-based, R&D-driven, biopharmaceutical leader
Learn more
Research & Development
Ecosystem for Health Innovation
Our Pipeline
Clinical Trials
Investigator Initiated Research
Takeda Ventures, Inc.
Areas of Focus
Oncology
Rare Diseases
Neuroscience
Gastroenterology
Plasma-Derived Therapies
Vaccines
Alliances & Partnerships
Partnering with Takeda
Takeda Digital Ventures
Our Products
Manufacturing
Innovation Story
Access to Medicines
Our Approach and Our Position
Hear from Patients
Driving Impact with Partners
Pre- Approval Access
Suppliers
Sustainable Procurement
Supplier Code of Conduct
Supplier Diversity
Pharmaceutical Supply Chain Initiative
Supplier Qualification & Due Diligence
Shire Supplier Information
Takeda Supplier Solutions Portal
Supplier Registration Process via Ariba Commerce Cloud
T-CiRA
About T-CiRA
Leaders Message
What we do
Portfolios
Project members
Inside T-CiRA
Research Achievements
We focus on our core therapeutic areas.
LEARN MORE
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
Takeda Leaders Highlight Continued Business Transformation at Virtual J.P. Morgan Healthcare Conference
A Look Inside Takeda’s Wave 1 Pipeline
Quality at Takeda
The Key Elements at the Heart of Our Innovation
Caring
New In Their Shoes Experience Simulates Short Bowel Syndrome with Intestinal Failure
Shifting paradigms of COVID-19 reflections from the 75th UN General Assembly
Improving Access to Healthcare in Remote Communities
Harnessing the Power of People to Transform Health Care
Shared Knowledge for a Better Life for All
Heritage
Keys to Aging Gracefully
Harnessing the power of people to transform health care
LEARN MORE
Corporate Responsibility
Takeda's CSR
Takeda is committed to addressing the world’s biggest challenges to sustainable development over the long term.
LEARN MORE
Programs in Action
Takeda Chair in Global Child Health
Takeda Initiative for the Global Fund
Global CSR Program
Apply for Funding
Frequently Asked Questions
Leaders Driving Change
Sustainable Value Report
Introduction
Patient
People
Planet
Governance
Appendix
Human Rights
Labor
Environment
Commitment to Carbon Neutrality
Emission Reduction Targets
Anti-Corruption
TAKEDA LIFE THEATER
Partner with our Global CSR Program
LEARN MORE
HOME
Newsroom
Statements
Share:
Newsroom
News Releases
Statements
In the News
Featured Topics
Corporate Materials
Social Media
Message from the CEO
Statements
Enter
All
Last 12 months
2020
2019
2018
2017
2016
2015
2014
September 2020
September 1, 2020
9/1/2020
Update on the U.S. Development Program for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
June 2020
June 22, 2020
6/22/2020
Update of the Financial Impact of the European Commission’s Decision to Release Takeda from Commitment to Divest Shire’s Pipeline Compound SHP647
June 17, 2020
6/17/2020
Regarding a Warning Letter from the U.S. Food and Drug Administration
June 2019
June 5, 2019
6/5/2019
Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial
January 2019
January 3, 2019
1/3/2019
Takeda Notes Court Sanction of the Scheme of Arrangement with respect to the Acquisition of Shire plc
October 2018
October 26, 2018
10/26/2018
Takeda comments on ongoing Phase 1 review by the European Commission of the proposed acquisition of Shire plc
May 2018
May 8, 2018
5/8/2018
Takeda Statement Regarding Press Reports
April 2018
April 24, 2018
4/24/2018
Takeda Statement Regarding Shire plc
April 20, 2018
4/20/2018
Takeda Statement Regarding Improved Proposal for Shire plc
1
2
3
TOP